

Haematologica  
HAEMATOL/2019/237230  
Version 3

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433

Glen Lew, Yichen Chen, Xiaomin Lu, Susan R. Rheingold, James A. Whitlock, Meenakshi Devidas, Caroline A. Hastings, Naomi J. Winick, William L. Carroll, Brent L. Wood, Michael J. Borowitz, Michael A. Pulsipher, and Stephen P. Hunger

Disclosures: RESEARCH SUPPORT This study was supported by grants U10 CA98543, U10 CA98413, U10 CA180886, 1U24-CA196173 and U10 CA180899 from the National Institutes of Health, and by St. Baldrick's Foundation. AUTHOR DISCLOSURES GL: Travel (Bristol-Myers-Squibb); MD: Honoraria (Pfizer, Novartis, PSI), Travel (PSI); SRR: Employment (Axovant (I), Endo Pharmaceuticals (I)), Stock or Other Ownership (Axovant (I)); JAW: Honoraria (prIME Oncology, Medical Learning Group, Wave Healthcare, Jazz Pharmaceuticals), Consulting or Advisory Role (Spectrum Pharmaceuticals, Amgen, Eviti, Janssen-Ortho), Research Funding (GlaxoSmithKline, Novartis, Kite Pharma, Pfizer); WLC: Other Relationship (Amgen); BLW: Honoraria (Amgen, Seattle Genetics, AbbVie, Janssen Pharmaceuticals), Research Funding (Amgen (Inst), Seattle Genetics (Inst), Pfizer (Inst), Juno Therapeutics (Inst), BiolineRx (Inst), Biosight (Inst), Stemline Therapeutics (Inst)); MJB: Honoraria (Beckman Coulter), Research Funding (Becton Dickinson, Amgen); SPH: Stock/Ownership Interests (Amgen, Merck, Pfizer), Honoraria (Amgen), Consulting (Novartis)

Contributions: GL wrote the primary manuscript and chaired the study YC, XL, and MD performed data analysis and contributed to the manuscript BLW and MJB performed minimal residual disease testing for the study GL, SRR, JAW, CAH, NJW, WLC, MAP and SPH developed the study, supervised the conduct of the study, interpreted the data, and contributed to the manuscript.